News headlines about Theravance Biopharma (NASDAQ:TBPH) have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Theravance Biopharma earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.0772949542175 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:
- Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial … (prnewswire.com)
- Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018 (finance.yahoo.com)
- Theravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to … (prnewswire.com)
- Theravance Biopharma (TBPH) Highlights Submission of IMPACT Data to EMA to Support Expanded Label for Trelegy Ellipta (streetinsider.com)
- Theravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to Support Expanded Label for Trelegy Ellipta (finance.yahoo.com)
A number of analysts have weighed in on the company. BidaskClub raised Theravance Biopharma from a “strong sell” rating to a “sell” rating in a research report on Friday, February 9th. Leerink Swann increased their target price on Theravance Biopharma from $45.00 to $48.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th. Robert W. Baird reissued a “sell” rating and set a $22.00 target price on shares of Theravance Biopharma in a research note on Wednesday, November 1st. Cantor Fitzgerald set a $55.00 price objective on Theravance Biopharma and gave the company a “buy” rating in a research note on Wednesday, October 25th. Finally, ValuEngine downgraded Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $42.00.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.